ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US
AstraZeneca today announced that it has completed its agreement with Perrigo
Company plc for the divestment of US rights to Entocort® (budesonide), a
gastroenterology medicine for patients with mild to moderate Crohn’s disease, an
area of medicine outside AstraZeneca’s strategic focus.
Upon completion of the agreement, Perrigo paid AstraZeneca $380 million to
acquire the rights to sell Entocort capsules and the authorised generic Entocort
capsules marketed by Par Pharmaceuticals. The transaction does not include the
transfer of any AstraZeneca employees or facilities.
The agreement completes the global divestment of Entocort, following the
agreement entered into in July 2015 with Tillotts Pharma AG, part of the Zeria
Group, for the divestment of global rights to Entocort outside the US. The
divestment further emphasises AstraZeneca’s strategic focus on three main
therapy areas. The transaction does not impact AstraZeneca’s financial guidance
for 2015.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of diseases in three main therapy areas –
respiratory, inflammation, autoimmune disease (RIA), cardiovascular and
metabolic disease (CVMD) and oncology – as well as in infection and
neuroscience. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit: www.astrazeneca.com
CONTACTS
Media Enquiries
Esra Erkal-Paler UK/Global +44 20 7604 8030
Neil Burrows UK/Global +44 20 7604 8032
Vanessa Rhodes UK/Global +44 20 7604 8037
Karen Birmingham UK/Global +44 20 7604 8120
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Enquiries
UK
Thomas Kudsk Larsen Oncology +44 7818 524185
Eugenia Litz RIA +44 7884 735627
Nick Stone CVMD +44 7717 618834
Craig Marks Finance +44 7881 615764
Christer Gruvris Consensus Forecasts +44 7827 836825
US
Lindsey Trickett Oncology, ING +1 240 543 7970
Mitch Chan Oncology +1 240 477 3771
Dial / Toll-Free +1 866 381 7277
Key: RIA – Respiratory, Inflammation and Autoimmunity, CVMD – Cardiovascular and
Metabolic Disease,
ING – Infection, Neuroscience and Gastrointestinal
15 December 2015
-ENDS-
